BioSpace News Archive

Business

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate Inc. (NASDAQ: CING) (Cingulate or the Company) today provided financial results for the quarter ended September 30, 2023, as well as a clinical and business update.

November 13, 2023
·
10 min read
Business

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals, Inc. (OTC: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended September 30, 2023, and provided a business update.

November 13, 2023
·
11 min read
Business

RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today reported financial results for the third quarter ended September 30, 2023 and provided an update on key corporate initiatives.

November 13, 2023
·
8 min read
Business

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023

ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, announced its unaudited financial results for the quarter ended September 30, 2023.

November 13, 2023
·
10 min read
Business

Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

Allakos Inc., a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, provided a business update and reported financial results for the third quarter ended September 30, 2023.

November 13, 2023
·
7 min read
Business

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

ALX Oncology Holdings Inc., an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

November 13, 2023
·
12 min read
Business

Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, reported recent business progress and third-quarter 2023 financial results.

November 13, 2023
·
8 min read
Business

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.

November 13, 2023
·
10 min read
Business

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

November 13, 2023
·
11 min read
Business

Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter of 2023.

November 13, 2023
·
17 min read